NO20050537L - Anvendelse av HMGB1 i behandlingen av vevsskade og/eller for a fremme vevsreparasjon - Google Patents

Anvendelse av HMGB1 i behandlingen av vevsskade og/eller for a fremme vevsreparasjon

Info

Publication number
NO20050537L
NO20050537L NO20050537A NO20050537A NO20050537L NO 20050537 L NO20050537 L NO 20050537L NO 20050537 A NO20050537 A NO 20050537A NO 20050537 A NO20050537 A NO 20050537A NO 20050537 L NO20050537 L NO 20050537L
Authority
NO
Norway
Prior art keywords
treatment
tissue
hmgb1
promote
hmgbl
Prior art date
Application number
NO20050537A
Other languages
English (en)
Inventor
Marco Emilio Bianchi
Roberta Palumbo
Maurizio Colognesi Capogrossi
Federica Limana
Antonia Germani
Original Assignee
Ct Cardiologico Monzino Spa Ir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Cardiologico Monzino Spa Ir filed Critical Ct Cardiologico Monzino Spa Ir
Publication of NO20050537L publication Critical patent/NO20050537L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)

Abstract

Det beskrives et preparat omfattende en effektiv mengde HMGBl-protein eller fimksjonelle deler derav, eller HMGBl-ekspresjonsvektorer for behandlingen av vevsskade og/eller for å fremme vevsreparasjon og regenerering. Det er videre beskrevet et preparat omfattende en effektiv mengde av en antagonist av HMGBl-proteinet for behandlingen av bivirkninger indusert gjeimom nekrotisk vev, slik som rekruttering og aktivering av myeloidceller, tap av barrierefimksjonen til endotelia, ødem.
NO20050537A 2002-07-03 2005-02-01 Anvendelse av HMGB1 i behandlingen av vevsskade og/eller for a fremme vevsreparasjon NO20050537L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39399402P 2002-07-03 2002-07-03
PCT/IT2003/000265 WO2004004763A2 (en) 2002-07-03 2003-04-29 Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair

Publications (1)

Publication Number Publication Date
NO20050537L true NO20050537L (no) 2005-02-01

Family

ID=30115667

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050537A NO20050537L (no) 2002-07-03 2005-02-01 Anvendelse av HMGB1 i behandlingen av vevsskade og/eller for a fremme vevsreparasjon

Country Status (14)

Country Link
US (1) US20060035851A1 (no)
EP (1) EP1519957B1 (no)
JP (1) JP2005537253A (no)
KR (1) KR20050054907A (no)
CN (1) CN1671742A (no)
AT (1) ATE424416T1 (no)
AU (1) AU2003228099A1 (no)
CA (1) CA2491321A1 (no)
DE (1) DE60326453D1 (no)
IL (1) IL166022A0 (no)
MX (1) MXPA05000302A (no)
NO (1) NO20050537L (no)
RU (1) RU2005102593A (no)
WO (1) WO2004004763A2 (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7151082B2 (en) 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
AU2004272607B2 (en) 2003-09-11 2008-11-06 Cornerstone Therapeutics Inc. Monoclonal antibodies against HMGB1
AU2005264185A1 (en) * 2004-07-20 2006-01-26 Centro Cardiologico Monzino S.P.A. - Irccs Use of HMGB1 for wound healing
US8129130B2 (en) 2004-10-22 2012-03-06 The Feinstein Institute For Medical Research High affinity antibodies against HMGB1 and methods of use thereof
EP1812065A4 (en) 2004-10-22 2009-09-02 Medimmune Inc HIGH AFFINITY ANTIBODIES AGAINST HMGB1 AND METHODS OF USE
US7795314B2 (en) 2005-06-01 2010-09-14 Cytokine Pharmasciences, Inc. Protective role of semapimod in necrotizing enterocolitis
WO2007031100A1 (en) * 2005-09-14 2007-03-22 Ostini, Marco Active immunotherapy of life-threatening systemic inflammation
CA2631212A1 (en) 2005-11-28 2007-07-05 Medimmune, Llc Antagonists of hmgb1 and/or rage and methods of use thereof
US7829097B2 (en) 2006-02-06 2010-11-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of HMGB1 for protection against ischemia reperfusion injury
JP3882090B1 (ja) * 2006-05-19 2007-02-14 国立大学法人 岡山大学 脳血管攣縮抑制剤
AU2014200688C1 (en) * 2006-10-30 2016-04-21 Genomix Co., Ltd. Pharmaceuticals that promote functional regeneration of damaged tissues
DK2055308T3 (en) * 2006-10-30 2017-07-17 Genomix Co Ltd PHARMACEUTICALS FOR PROMOTING FUNCTIONAL REGENERATION OF DAMAGED TISSUE
TW200902063A (en) 2007-02-15 2009-01-16 Univ Kumamoto Therapeutic agent comprising antibody capable of specifically binding to human hmgb-1 as active ingredient
JP5660889B2 (ja) * 2008-04-30 2015-01-28 株式会社ジェノミックス 末梢循環への骨髄由来多能性幹細胞動員薬
RU2010148785A (ru) * 2008-04-30 2012-06-10 Дженомикс Ко., Лтд. (Jp) Фармацевтическое средство для стимуляции функциональной регенерации поврежденной ткани
US9919010B2 (en) 2008-04-30 2018-03-20 Genomix Co., Ltd. Method for collecting functional cells in vivo with high efficiency
AU2010312537A1 (en) 2009-10-28 2012-05-17 Genomix Co., Ltd. Tissue-regeneration promoter using recruitment of bone marrow mesenchymal stem cells and/or pluripotent stem cells in blood
RU2012157399A (ru) * 2010-06-18 2014-07-27 КсайберСайенс ГмбХ Пептиды в качестве активных агентов для стабилизации биологических барьеров
CN102375064A (zh) * 2010-08-26 2012-03-14 杭州华得森生物技术有限公司 用酶联免疫法检测人体中hmga2含量的体外诊断试剂盒
WO2012030919A2 (en) * 2010-09-01 2012-03-08 Thomas Jefferson University Composition and method for muscle repair and regeneration
ES2684718T3 (es) 2011-04-26 2018-10-04 StemRIM Inc. Péptido para inducir regeneración de tejido y uso del mismo
WO2014016417A1 (en) * 2012-07-26 2014-01-30 Ospedale San Raffaele Srl Hmgb1 variants and uses thereof
CA2889275C (en) * 2012-10-25 2021-06-15 Katsuto Tamai Novel method for treating cardiac infarction using hmgb1 fragment
RU2649069C2 (ru) * 2012-10-25 2018-04-02 Дженомикс Ко., Лтд. Новый способ лечения повреждения спинного мозга с применением фрагмента hmgb1
CN103316378B (zh) * 2013-06-27 2014-07-16 重庆大学 一种hmgb 1修饰的骨组织工程支架材料及其制备方法
KR102365492B1 (ko) 2015-04-22 2022-02-18 삼성전자주식회사 웨어러블 기기
RU2768186C2 (ru) 2015-12-11 2022-03-23 Рупрехт-Карлс-Университет Гейдельберг Комбинированные лекарственные средства, содержащие модуляторы pkm2 и hmgb1
CN109310741A (zh) * 2016-04-29 2019-02-05 阿拉伊姆药品公司 用于预防和治疗与组织损伤相关的疾病和障碍的组织保护肽
CN106244589A (zh) * 2016-08-01 2016-12-21 中国人民解放军第四军医大学 靶向hmgb1基因的rna干扰片段及其应用
TWI805565B (zh) * 2017-01-27 2023-06-21 日商斯德武利姆股份有限公司 心肌病、陳舊性心肌梗塞及慢性心臟衰竭的治療藥物
BR112019021230A2 (pt) 2017-04-25 2020-06-02 Shionogi & Co., Ltd. Peptídeos, composições que os compreende e uso dos mesmos
WO2019107530A1 (ja) 2017-12-01 2019-06-06 株式会社ステムリム 炎症性腸疾患の治療薬
CN111381050B (zh) * 2020-04-21 2023-06-20 南通大学 Reg3β/ HMGB1环路调控EAM小鼠巨噬细胞再编程的实验方法
WO2023037562A1 (ja) * 2021-09-07 2023-03-16 国立大学法人大阪大学 肺炎の治療薬

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19548122A1 (de) * 1995-12-21 1997-06-26 Joern Prof Dr Bullerdiek Nukleinsäuresequenzen von Genen der High Mobility Group Proteine sowie Verwendungen derselben
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US6610713B2 (en) * 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
CA2440480A1 (en) * 2001-03-15 2002-09-26 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions
US7754217B2 (en) 2001-03-16 2010-07-13 Bio3 Research Srl HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases
CA2447576C (en) * 2001-05-15 2014-04-08 North Shore-Long Island Jewish Research Institute Use of hmg fragments as anti-inflammatory agents

Also Published As

Publication number Publication date
WO2004004763A3 (en) 2004-02-26
CA2491321A1 (en) 2004-01-15
CN1671742A (zh) 2005-09-21
WO2004004763A2 (en) 2004-01-15
DE60326453D1 (de) 2009-04-16
AU2003228099A1 (en) 2004-01-23
RU2005102593A (ru) 2005-10-10
US20060035851A1 (en) 2006-02-16
JP2005537253A (ja) 2005-12-08
ATE424416T1 (de) 2009-03-15
EP1519957B1 (en) 2009-03-04
IL166022A0 (en) 2006-01-15
KR20050054907A (ko) 2005-06-10
EP1519957A2 (en) 2005-04-06
MXPA05000302A (es) 2005-08-19

Similar Documents

Publication Publication Date Title
NO20050537L (no) Anvendelse av HMGB1 i behandlingen av vevsskade og/eller for a fremme vevsreparasjon
TR200100149T2 (tr) Dual anjiyotensin endotelin alıcı antagonistleri olarak bifenil-sülfonamitler
WO2006116731A3 (en) Personal care compositions comprising a dipeptide
EA200602062A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
ATE446313T1 (de) Muteine von tränen-lipocalin
EA200701036A1 (ru) Лактамные соединения и их применение в качестве фармацевтических препаратов
FI953748A (fi) Yhdisteitä, joilla on sekä voimakas kalsium antagonisti- että antioksidanttiaktiivisuus sekä niiden käyttö solua suojaavina aineina
EA200000911A1 (ru) Новые кристаллические формы антивирусного соединения бензимидазола
EA200700251A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
BR0306665A (pt) Uso de zeìna nativa para aperfeiçoamento do estado do cabelo e agentes
BR0311939A (pt) composição farmacêutica, método para tratar inflamação em um mamìfero e uso de uma citocina protetora de tecido orgánico
NO20070372L (no) Amidoforbindelser og anvendelse derav som farmasoytiske preparater
DE50207442D1 (de) Behandlung der akne mit lipoxygenase inhibitoren
EA200300738A1 (ru) Защита, восстановление и усиление эритропоэтинреактивных клеток, тканей и органов
ATE464287T1 (de) Cyclohexyl-sulphone als gamma-sekretase- inhibitoren
AR046933A1 (es) Eficacia de humectacion mejorada mediante el uso de hidroxialquilurea
TR200201874T2 (tr) Proteaz inhibitörleri olarak yeni bileşikler ve bileşimler.
CY1107467T1 (el) Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων
BRPI0511367B8 (pt) uso de uma composição,composição, uso de vip e/ou de um fragmento ativo do mesmo
NO20071378L (no) Tiazolo-naftylsyrer.
ATE269113T1 (de) Sprühfähige wundversorgungszusammensetzung
NO20075815L (no) Formuleringer og metoder for behandling av amyloidose
ATE445389T1 (de) Liposomale glucocorticoide
WO2004039832A3 (en) Leptin-related peptides

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application